11% Undervalued? Vertex Pharmaceuticals (VRTX) Following New ALYFTREK Data

Vertex Pharmaceuticals (VRTX) just put fresh clinical data for ALYFTREK in front of cystic fibrosis specialists at the North American Cystic Fibrosis Conference, highlighting early pancreatic function recovery in some very young children.

Vertex Pharmaceuticals’ recent ALYFTREK data arrives while the share price has climbed 12.82% year to date and the 1-year total shareholder return of 25.08% points to solid momentum, with a 5.09% 90-day share price return suggesting that investors are leaning into the broader cystic fibrosis and pipeline story despite a softer 30-day patch.

Scan beyond Vertex Pharmaceuticals and see how other specialists in complex conditions are positioning for potential gains with a curated list of 34 healthcare AI stocks.

So is Vertex Pharmaceuticals’ recent climb, against a softer 30 day patch, mostly a verdict on its cystic fibrosis engine, or a swing in sentiment that the current valuation already bakes in?

Most Popular Narrative: 11% Undervalued

Vertex Pharmaceuticals is trading at a last close of $510.08, while the most followed narrative anchors fair value at $571.39 using a 7.51% discount rate. That gap frames the current move in the stock as less a speculative surge and more a reflection of expectations around cystic fibrosis plus newer renal and endocrinology assets.

Rapid progress in launching and expanding access for new therapies such as ALYFTREK in cystic fibrosis, CASGEVY in sickle cell disease and beta thalassemia, and JOURNAVX in acute pain across additional geographies and younger patient groups is supported by raised 2026 revenue guidance to US$13.1b to US$13.2b. This is expected to influence top line revenue and operating leverage.

See why 139 investors see Vertex Pharmaceuticals as 11% undervalued.

Result: Fair Value of $571.39 (UNDERVALUED)

Still, the narrative around Vertex Pharmaceuticals can break if cystic fibrosis pricing weakens further, or if the Crinetics acquisition integration drags on cash and margins.

Find out about the key risks to this Vertex Pharmaceuticals narrative.

Next Steps

Curious whether the optimism in this Vertex Pharmaceuticals story fully holds up under your own scrutiny, or if the market is getting ahead of itself? Take a closer look at what supporters are focusing on and review the 3 key rewards.

Looking for more Vertex Pharmaceuticals investment ideas?

Before moving on, give yourself an edge by lining up a few more potential candidates, so Vertex Pharmaceuticals sits alongside other well-researched ideas on your radar.

• Target resilient compounding potential by scanning a curated 31 resilient stocks with low risk scores that keeps balance sheet strength and risk scores front and center.
• Hunt for mispriced quality by reviewing a focused 20 high quality undiscovered gems built around strong fundamentals that the wider market may not be watching yet.
• Strengthen your defense with a 8 dividend fortresses that zeroes in on higher yielding companies where income potential sits alongside an emphasis on stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com